Literature DB >> 1499100

Association between expression of transforming growth factor-alpha and progression of hepatocellular foci to neoplasms.

W K Kaufmann1, Y Zhang, D G Kaufman.   

Abstract

Hepatocarcinogenesis was initiated in rats with a single dose of either of two chemical mutagens--benzo[a]pyrene diolepoxide I and methyl(acetoxymethyl)nitrosamine--administered 15 h after partial hepatectomy. The development of hepatocellular foci and neoplasms was then promoted with dietary phenobarbital given for 45 or 62 weeks. Formalin-fixed tissue specimens that contained hepatic neoplasms and altered hepatocellular foci were screened for expression of the oncodevelopmental marker glutathione-S-transferase (placental form) (GSTP) and transforming growth factor-alpha (TGF-alpha) using immunohistochemistry. All (100%) hepatocellular carcinomas expressed both GSTP and TGF-alpha, as did most hepatocellular adenomas (greater than 80%). However, quantitative stereologic analysis of treated and control livers revealed that GSTP-positive foci were 10-30 times more frequent than TGF-alpha-positive foci. Foci with homogeneous expression of GSTP generally displayed heterogeneous expression of TGF-alpha with reaction product most prominent at their peripheries. Less frequently homogeneous TGF-alpha-positive foci were seen within GSTP-positive foci. The average volumes of those GSTP-positive foci that also expressed TGF-alpha were significantly greater than those of the entire sets of GSTP-positive foci. These results suggest that expression of TGF-alpha may distinguish a subset of GSTP-positive foci that have a growth advantage and increased probability of progression to neoplasia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1499100     DOI: 10.1093/carcin/13.8.1481

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

Review 1.  The functions of cytokines and their uses in toxicology.

Authors:  J R Foster
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

2.  Overexpression of insulin receptor substrate-1 emerges early in hepatocarcinogenesis and elicits preneoplastic hepatic glycogenosis.

Authors:  D Nehrbass; F Klimek; P Bannasch
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

Review 3.  Stage-specific gene expression during hepatocarcinogenesis in the rat.

Authors:  H C Pitot
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Hepatocellular neoplasms induced by low-number pancreatic islet transplants in streptozotocin diabetic rats.

Authors:  F Dombrowski; P Bannasch; U Pfeifer
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

5.  Autocrine growth stimulation of SW403 colon carcinoma cell line is caused by transforming-growth-factor-alpha-mediated epidermal growth factor receptor activation.

Authors:  T Hirsch; S Eggstein; S Frank; E Farthmann; B U von Specht
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  Overexpression of transforming growth factor-alpha causes liver enlargement and increased hepatocyte proliferation in transgenic mice.

Authors:  E M Webber; J C Wu; L Wang; G Merlino; N Fausto
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

7.  Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha.

Authors:  J C Wu; G Merlino; N Fausto
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

8.  Sparse distribution of hepatocyte growth factor-producing cells inside hepatocellular foci in rats treated with hepatocarcinogens.

Authors:  T Imai; M Ichinose; T Yanai; T Masegi; T Nakamura; T Tsukamoto; K Kitoh; M Tatematsu
Journal:  Jpn J Cancer Res       Date:  1997-07

9.  Transforming growth factor-alpha induces the differentiation of sarcomatoid cholangiocarcinoma cells.

Authors:  M Enjoji; M Nakashima; M Nakamuta; H Nawata
Journal:  Jpn J Cancer Res       Date:  2000-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.